ACAM2000 smallpox and mpox (vaccinia) vaccine, live Updated Nov 2
ACAM2000 is an approved, revenue-generating product with no pending FDA binary catalyst. Watch for U.S. government contract option exercises (the 10-year ASPR deal has annual renewals) and further international approvals, which drive lumpy quarterly revenue. The Q3 2026 revenue miss and lowered guidance are the near-term headwind to watch.
- ACAM2000 is one of only two FDA-approved vaccines for both smallpox and mpox, with a long track record since 2007 and a place in the U.S. Strategic National Stockpile.
- The U.S. government has a 10-year contract with annual option renewals: a $56M modification in September 2025 and a $52.7M modification in June 2026, with total projected 2025 ACAM2000 sales exceeding $120 million.
- International expansion is underway: Saudi Arabia approved ACAM2000 in May 2026 and Singapore approved an expanded mpox indication, opening new non-U.S. revenue streams.
- ACAM2000 faces competition from JYNNEOS (Bavarian Nordic), a safer non-replicating vaccine that the CDC prefers for mpox outbreaks and that has largely replaced ACAM2000 in clinical use.
- ACAM2000 is a live replicating vaccinia virus vaccine with a known safety risk of myocarditis and other serious adverse reactions, limiting its addressable population.
- Revenue is highly dependent on lumpy U.S. government contract timing: Q3 2026 Smallpox MCM product revenues (which include ACAM2000) fell 68% year-over-year due to delivery timing, contributing to a 52% total revenue decline and a net loss.